Show simple item record

dc.creatorMiljević, Cedo D
dc.creatorNikolić, Milan R
dc.creatorNikolić-Kokić, Aleksandra
dc.creatorJones, David R
dc.creatorNiketić, Vesna P
dc.creatorLecić-Tosevski, Dusica M
dc.creatorSpasić, Mihajlo
dc.description.abstractObjective: Despite clozapine's unique effectiveness in patients with schizophrenia, a number of adverse effects have been recognised including abnormalities in lipid and glucose metabolisms. A high clozapine level in red blood cells (RBCs) and disturbed anti-oxidant enzyme activities in blood from schizophrenic patients prompted us to investigate lipid status and anti-oxidant enzyme defence in the blood of chronic schizophrenic patients on long-term clozapine therapy. Methods: Plasma lipids, RBC anti-oxidant enzyme activities and haemoglobin (Hb) content were measured using established procedures in a group of eighteen chronically-medicated (average 630 days of therapy) schizophrenic patients receiving clozapine (average dose of 295 mg/day) and data were compared with those from a group of eighteen well-matched normal controls. Results: Significantly higher levels of plasma triglycerides (by 47%, p<0.01) and total cholesterol and phospholipids (by 8% and 11%, respectively p<0.05) in patients were found. CuZn-superoxide dismutase (SOD1) activity was markedly higher (by 35%, p<0.001) while selenium-dependent glutathione peroxidase (GSH-Px1) activity was markedly lower (by 41%, p<0.001) in patients. In addition, metHb and HbA1c levels in patients were significantly higher (by 58% and 25%. respectively p<0.001). SOD1 activity was negatively correlated (p<0.001) to GSH-Px1 activity in patients. Conclusions:The findings support the view that ongoing oxidative stress may be a mechanism by which clozapine induces some adverse effects that increase the risk of diabetes and metabolic syndrome. If valid, this would indicate that in parallel with long-term clozapine treatment, schizophrenic patients could be encouraged to make some lifestyle changes to limit the detrimental effects of the medication. (C) 2009 Elsevier Inc. All rights reserved.en
dc.description.sponsorshipMinistry of Science and Technological Development of the Republic of Serbia [142017, 143034]sr
dc.sourceProgress in Neuro-Psychopharmacology & Biological Psychiatrysr
dc.titleLipid status, anti-oxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patientsen
dcterms.abstractЈонес, Давид Р; Никетић, Весна П; Спасић, Михајло Б.; Николић-Кокић, Aлександра; Миљевић, Цедо Д; Николић, Милан Р; Лецић-Тосевски, Дусица М;

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record